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Abstract: Background: The dimensionality of depression and anxiety instruments have recently
been a source of controversy. Objectives and Design: in a European-wide sample of patients after
Traumatic Brain Injury (TBI), we aim to examine the factorial structure, validity, and association
of the Patient Health Questionnaire for depression (PHQ-9) and the Generalized Anxiety Disorder
(GAD-7) instruments. This study is based on longitudinal observational data. We conducted analyses
of factorial structure and discriminant validity of outcomes six-months after TBI. We also examined
the prevalence, co-occurrence, and changes of scores on the PHQ-9 and GAD-7 at 3-, 6-, and 12-month
post-TBI assessments. Participants: At six-months post-TBI assessment, 2137 (738 (34.5%) women)
participants completed the PHQ-9 and GAD-7 questionnaires. For the longitudinal analysis, we had
1922 participants (672 (35.0%) women). Results: The results of exploratory factor analysis suggested
a general latent construct underlying both PHQ-9 and GAD-7 measures. Confirmatory factor analyses
showed a slight improvement in the fit indices for the bifactorial model. The Omega hierarchical
test clearly differentiated two subfactors of PHQ-9 and GAD-7 items over and above the underlying
general factor; however, most of the variance (85.0%) was explained by the general factor and
the explained variance of the subfactors was small. The PHQ-9 and GAD-7 performed similarly
in detecting post-traumatic stress disorder (PTSD). As defined by conventional cut-offs, depression
and anxiety have different prevalence rates in the sample. The scales also differed in their relationships
with the short form of health survey (SF-36v2) subscales. The longitudinal analysis showed high
stability of depression and anxiety symptoms: 49–67% of the post-TBI patients with comorbid
depression and anxiety reported the persistence of the symptoms over time. Discussion: The factorial
structure analysis favors a general latent construct underlying both depression and anxiety scales
among patients after TBI. We discuss the implications our findings and future research directions.
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1. Introduction
Depression and anxiety are among the most commonly experienced mental health disorders
in both the general population and different medical conditions [1,2]. However, depression and anxiety
are often under-recognized in medical settings [3], and this can complicate the patients’ recovery [4].
Among individuals with a history of Traumatic Brain Injury (TBI), depression and anxiety
are the most common mental health problems [5,6]. TBI is characterized by alterations of brain
function, including loss of consciousness, impaired memory, neurological deficit (e.g., loss of balance),
and alteration of mental state at the time of injury [7]. TBI severity varies from mild to moderate and
severe, and over 90% of the TBI cases are mild TBIs [7]. The prevalence of TBI is high, with 50 million
annual worldwide occurrences: Nearly half of the world’s population will suffer from some form of
TBI at least once over their lifetime [7].
When remaining untreated, depression and anxiety not only impede the patient’s recovery from
TBI, but also leave a lasting impairment in their post-TBI life, such as poorer social functioning and
more post-concussion symptoms [8–10]. The prevalence rate of depression among patients after TBI is
estimated to be between 15% and 27% [8,11] and for anxiety between 23% and 29% [5,10,12].
There is a growing body of literature reporting the coexistence and comorbidity of depression
and anxiety [13–15]. The comorbidity of depression and anxiety has also been found in TBI [9].
As a result, there is a growing call to investigate depression and anxiety together and further examine
their relationship and comorbidity not only cross-sectionally but also over time [5].
Furthermore, conceptually, depression and anxiety are distinct constructs, although they are part
of the same category of mood disorders. For instance, anxiety was predominantly conceptualized as
an unpleasant feeling and worrying reaction to a perceived future threat and depression as a diminished
activity and loss of pleasure and interest [16].
Empirically, the factorial structure analysis of depression and anxiety has resulted in contradictory
evidence not only in the composite scale of depression and anxiety (such as Depression Anxiety Stress
Scales—21 (DASS-21): [17]; Mood and Anxiety Symptom Questionnaire (MASQ): [18]; Hospital Anxiety
and Depression Scale (HADS): [19]), but also in the scales that aim to measure the two constructs
of depression and anxiety separately. In the composite measurement of depression and anxiety,
using HADS for instance, previous research proposed various hierarchical structure of this scale
including a one-factorial [20], two-factorial [21,22], three-factorial [23], and a bifactorial model [24,25].
With the use of a bifactorial model, which depicts a general psychological distress factor encompassing
all items and two orthogonal grouping subfactors of depression and anxiety, most variance was
explained by the general factor and the subfactors’ contribution was negligible [24,25]. Consequently,
a systematic review of studies on the latent structure of HADS cast doubt on the ability of this measure
to reliably differentiate depression and anxiety and proposed a general latent construct of psychological
distress underlying the HADS measure [26].
Regarding the measurements that aim to screen patients with symptoms of depression and anxiety
separately, the widely used instruments are the nine-item Patient Health Questionnaire (PHQ-9; [27,28])
and the seven-item scale for Generalised Anxiety Disorder (GAD-7; [29]). Both PHQ-9 and GAD-7
items are based on the DSM-IV criteria for depression and anxiety [27,29] and proved to be valid
in a variety of different medical settings [see 10] including for patients after TBI, e.g., [5,30].
Dimensionality has not been thoroughly scrutinized on a composite measure of PHQ-9 and GAD-7.
In most studies, they were considered to be independent and unidimensional instruments (for a review,
see [10]), with few studies showing an extra somatic subdimension besides the cognitive affective
subdimension in both PHQ-9 and GAD-7 (e.g., [31]). Recently, Kroenke et al. [32] combined the PHQ-9
and GAD-7 items and with the use of bifactorial modeling proposed a composite measure of depression
and anxiety called the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS).
According to the bifactorial modelling terminology, PHQ-ADS is the general factor and the two PHQ-9
and GAD-7 scales are the subfactors. Despite the negligible contribution from the subfactors to
the explanation of scale variance, Kroenke et al. [32] stated that PHQ-ADS does not override the value
J. Clin. Med. 2020, 9, 873 3 of 21
of individual PHQ-9 and GAD-7 subfactors. However, they did not provide the evidence showing
the independent effect of PHQ-9 and GAD-7 over and above PHQ-ADS. In this study, we examine
the factorial structure of a composite measure PHQ-ADS in TBI and evaluate the subfactors PHQ-9
and GAD-7′s discriminant, construct, and predictive validity. We also look at the cross-sectional and
longitudinal comorbidity of depression and anxiety.
In sum, the aims of the present study are (1) to investigate the relation between scores of
PHQ-9 and GAD-7 instruments, (2) the factorial structure of the composite measure of PHQ-ADS,
and (3) the discriminant, construct, and predictive validity of the subfactors of PHQ-9 and GAD-7.
We examine the study objectives in a European sample of patients after TBI.
2. Methods
2.1. Participants
This study uses data from the Collaborative European NeuroTrauma Effectiveness Research in TBI
(CENTER-TBI (Core 2.0)) project [33]. CENTER-TBI is a longitudinal observational study involving
59 different medical and research centers in 18 countries. The CENTER-TBI study included 4509 patients
with a clinical diagnosis of TBI [34]. The inclusion criteria included being recruited within 24 h after TBI,
clinical indication for a CT-scan, lack of severe neurological disorders before the injury, and informed
consent [33]. We selected those who were 16 years of age or above (n = 4360) and survived the 6-months
post TBI (n = 3886). For the factorial structure analysis, we used the 6-month post-TBI data, in which
2137 participants (738 (34.5%) women, 1399 (65.5%) men) completed the psychological outcome
measures of PHQ-9 and GAD-7. These participants were recruited from three strata including patients
primarily admitted to the intensive care unit (ICU, 885 (41.4%) at the time of enrollment), patients
admitted to hospital ward (admission stratum, 805 (37.7%)), and patients evaluated in the emergency
room and discharged (ER, 447 (20.9%)). The cause of injury was mainly due to road accidents (40.71%
of incidence) and incidental fall (43.61%) and few patients reported their injury to be due to other
causes such as assault (3.93%) and suicide attempt (0.89%).
For the predictive validity and sequential comorbidity of depression and anxiety, we analyzed
1922 patients that had at least two out of the three time-point assessments (3, 6, and 12 months post-TBI:
672 (35.0%) women, 1250 (65.0%) men), from which 794 (41.3%) patients were recruited from the ICU,
761 (39.6%) from the admission stratum, and 376 (19.1%) from the ER.
2.2. Ethical Approval
The CENTER-TBI study has been conducted in conformance with all relevant local national ethical
guideline and regulatory requirements for recruiting human subjects, as well as with relevant data
protection, privacy regulations, and informed consent. The study obtained ethical clearance from both
the EU and the relevant institutions across all countries that were involved in the project. Informed
consent was also obtained from all participants according to national and local procedures (for a list of sites,
ethical committees, and ethical approval details, see https://www.center-tbi.eu/project/ethical-approval).
2.3. Instruments
Demographic information was collected at the time of enrollment into the study and included
participants’ sex, age, and educational background.
The Glasgow Coma Scale (GCS) assesses coma and impaired consciousness after TBI with scores
that were obtained at several time points within 24 h post-injury such as pre-hospital, first arrival at
hospital, and post-stabilization [35]. Following the IMPACT methodology [36], GCS scores were based
on the post-stabilization period, and when the score was not available at the post-stabilization stage,
the previous non-missing scores were used. The GCS categorizes injury into severe (3–8), moderate
(9–12), and mild (13–15).
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The Glasgow Outcome Scale, Extended (GOSE) was assessed at 6-months post-TBI to assess
functional disability and recovery after TBI [37]. The GOSE classifies functional outcomes into eight
categories: Dead (1), vegetative state (2), lower severe disability (3), upper severe disability (4), lower
moderate disability (5), upper moderate disability (6), lower good recovery (7), and upper good
recovery (8). In our study, we had patients with a GOSE score of 3 or above.
The PHQ-9 assesses the frequency and severity of symptoms of depression using nine 4-point
Likert-scaled items ranging from 0 (not at all) to 3 (nearly every day) [27] (Kroenke & Spitzer, 2002).
A total score ranging from 0 to 27 is obtained by summing across all items, with ordinary mean
substitution for missing items if no more than one third (no more than three items) are missing. The total
score can be categorized at a cutoff of 10 to differentiate between minimal/mild versus moderate/severe
depression [15,38]. However, a systematic review indicated that a cutoff of 8 might increase sensitivity
to depression [39]. We used both cut-off points.
The GAD-7 measures the frequency and severity of generalized anxiety disorder symptoms [29],
using seven 4-point Likert-scale items with a response format ranging from 0 (not at all) to 3 (nearly every
day). A total score ranging from 0 to 21 was obtained by summing all items with ordinary mean
substitution for missing items if less than one third (less than two items) were missing. The total
score can be categorized at a cutoff of 10 [15] or 8 to optimize the test’s sensitivity and specificity for
identifying other anxiety disorders [40].
The PHQ-ADS combines the PHQ-9 and GAD-7 scales as composite measure of mental distress [32].
The Short-Form-36v2 (SF-36v2; [41]) is a generic measure of physical and mental outcomes with
eight dimensions: Physical Functioning (PF, 10 items), Role Limitation due to Physical Health (RP,
4 items), Role Limitation due to Emotional Health (RE, 3 items), Social Functioning (SF, 2 items), Body
Pain (BP, 2 items), Vitality (VT, 4 items), Mental Health (MH, 5 items), General Health (GH, 5 items).
SF-36 is commonly used to measure TBI people’s health-related quality of life [42]. Higher scores
indicate better health-related quality of life.
The PTSD Checklist for DSM-5 (PCL-5; [43]) is a self-report instrument to assess symptoms
of post-traumatic stress disorder (PTSD) across four symptoms clusters defined in the DSM-5
(reexperiencing, avoidance, negative alterations in cognition and mood, and hyperarousal). Intensity
is assessed using 20 five-point Likert scaled items ranging from 0 (not at all) to 4 (extremely). A total
sum score exceeding a cutoff of 33 indicates a likely PTSD [43,44].
We used the translated versions of the PHQ-9 and GAD-7 questionnaires that were available
in the relevant languages (see https://www.phqscreeners.com/select-screener/36) and were shown to
be valid and invariant across different sex, patient strata, and languages [45]. Following a procedure
recommended by Acquadro, Conway, Giroudet, and Mear [46], GOSE and PCL-5 were translated,
back-translated, panel-reviewed, and finally underwent a cognitive debriefing with several patients
and healthy participants. The final versions were revised based on the cognitive debriefing results to
ensure the conceptual and linguistic equivalence of the scales with the original English language.
2.4. Statistical Analysis
We examined three different aspects of the PHQ-9 and GAD-7 tests: (a) Reliability, (b) factorial
validity using exploratory and Confirmatory Factor Analyses (CFA) and Omega hierarchical test,
and (c) discriminant, construct, and predictive validity.
Reliability: Reliability was first analyzed using Cronbach’s alpha and Lambda 2 of Guttmann’s
coefficient (λ2) separately for PHQ-9 and GAD-7 as well as for the composite measure of depression
and anxiety (PHQ-ADS). The item level descriptive statistics of the PHQ-ADS showed many
skewed-distributed items (Appendix A), creating a floor effect and violating the normality assumption.
Moreover, using the original response format, the initial CFA analysis shows dissatisfactory model
fit indices even with the use of ordinal estimator, the Weighted Least Square Mean and Variance
adjusted (WLSMV). Consequently, to examine the factorial structure, we dichotomized the items
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(see the note in Appendix A), with two values: 0 (no depression/no anxiety) and 1 (some degree of
depression/anxiety, collapsing the original scores from 1 to 3 into 1).
Factorial validity: Principal Axis Factoring (PAF) was used to determine the number of
factors for PHQ-ADS in a parallel analysis of the scree plots with the Kaiser–Guttman criterion.
To confirm the factorial structure of PHQ-ADS items, we used CFA with WLSMV estimator and
theta parameterization for ordinal variables. We compared models with a one-, two-, and bifactorial
structure. Finally, to examine the factorial structure reliability, we used McDonald’s Omega Hierarchical
test (OmegaH).
The OmegaH test evaluates the bifactorial structure of the scale, examining how the factorial
structure of the PHQ-ADS can be accounted for by: (a) a single general factor (g), representing
the shared explained variance of all items, and (b) a set of group factors in which additional variance
over and above the general factor can be explained by a subset of similar items [47,48]. As a result,
the OmegaH test examines the extent to which the test reflects a common trait and is a good test
for dimensionality of the latent construct. We used several different parameters from Omega test
including Omega general for the general factor and subfactors, OmegaH, Explained Common Variance
(ECV), and Percentage of Uncontaminated Correlation (PUC) [49,50]. Omega general assesses the unit
weighted variance of the general factor and the subfactors, whereas OmegaH estimates the proportion
of variance that can be attributed to the general factor, treating the variance due to the subfactors as
measurement error [48]. The ECV provides an assessment of the relative strength of the subfactors,
examining the variance explained by general factor divided by variance explained by both general
factor and subfactors [48]. In conjunction with ECV, PUC evaluates the percentage of unique correlation
estimating the general factor, providing additional information whether there is a bias in considering
the scale as unidimensional. Higher PUC values indicate lower variability in ECV coefficient. Sufficient
evidence of unidimensionality in the Omega hierarchical test of the bifactorial model depends of
the ECV coefficient (≥0.70), PUC (≥0.70), and OmegaH coefficient (≥0.70) [48].
We used the omega function with oblique rotation method, tetrachoric correlation matrix given
the ordinal nature of the rescaled responses, and the Schmid–Leiman transformation for a bifactorial
model [51]. Following suggestions from Rodrigues et al., [50] and Bonifay et al., [49], we conducted
various validity tests to further examine whether the subfactors of PHQ-9 and GAD-7 have distinct
explanatory contribution.
Discriminant validity: For discriminant validity, we compared the performance of PHQ-9 and
GAD-7 in detecting an anxiety related disorder, PTSD. We hypothesized that GAD-7 would have
a better odds ratio in classifying patients with PTSD correctly than would PHQ-9 [29,40]. For this
purpose, we applied logistic regression and cross tabulation for an odds ratio of correct classification.
Construct and predictive validity: For construct validity, we examined the relationship of PHQ-9
and GAD-7 with the SF-36v2. Using the longitudinal data, we examined whether anxiety precedes
depression, as assumed in previous literature (e.g., [52]). For this purpose, we analyzed the 3-, 6-,
and 12-month data. To do so, we divided the participants into two groups based on their GAD-7 score
at 3 or 6 months. Then we applied the McNemar’s test for the intra-individual changes of depression
symptom over time in each of the low and high anxiety group [53].
Sequential comorbidity. Finally, we examined the sequential comorbidity of depression and
anxiety using the McNemar–Bowker with a pairwise post-hoc analysis, which is an extension of
McNemar test for more than two groups. With the McNemar–Bowker test, we examined whether
the contingency table is symmetric such that the probability of cell (i, j) is equal to the probability
of change in the cell (j, i), and a significant result would indicate a change from i to j. We relied on
Cohen’s [54] criteria to assess the odds ratio (OR: Small effect <1.86, medium for 1.86–3.00, and large
for ≥3.00) and Cohen’s g (small effect size for <0.15, medium for 0.15–0.25, large for ≥0.25).
All analyses were conducted using R version 3.5.3, and the packages “lavaan” [55], and “psych” [51].
We exported the data from the Neurobot platform of the CENTER-TBI (https://center-tbi.incf.org/) and
used the “CENTER Core 2.0” dataset.
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3. Results
3.1. Respondents Characteristics
The basic demographic information and medical characterization of the study participants
(at six-months post-TBI assessment) for the overall sample, as well as for each sex separately, can
be seen in Table 1. The participants had a wide age range (M = 49.19, SD = 19.30, Mdn = 51,
range = 16–95), relatively high education background (1585 (83.1%) completed high school education
or more), and diverse linguistic backgrounds (see Table 1). The GOSE score showed that more than half
of the participants (62.8%) had good recovery, a quarter had moderate disability (25.7%), and 10.3%
had severe disability at six months after TBI.
Table 1. Descriptive characteristics of the sample.
Variable Overall Stratified
n 2137 Female (738) Male (1399)
Countries (n, (%))
The Netherlands 498 (23.3) 199 (40) 299 (60)
Italy 269 (12.6) 84 (31.2) 185 (68.8)
Norway 260 (12.2) 81 (31.2) 179 (68.8)
Spain 254 (11.9) 76 (29.9) 178 (70.1)
The UK 207 (9.7) 70 (33.8) 137 (66.2)
Finland 207(9.7) 83 (40.1) 124 (59.9)
Belgium 154 (7.2) 45 (29.2) 109 (70.8)
Sweden 60 (2.8) 28 (46.7) 32 (53.3)
France 52 (2.4) 9 (17.3) 43 (82.7)
Others 176 (8.2) 63 (35.8) 113 (64.2)
Age groups (n, (%))
(16–24) 325 (15.2) 95 (29.2) 230 (70.8)
(25–34) 262 (12.3) 78 (29.8) 184 (70.2)
(35–44) 274 (12.8) 67 (24.5) 207 (75.5)
(45–54) 357 (16.8) 130 (36.4) 228 (63.9)
(55–64) 397 (18.6) 146 (36.8) 251 (63.2)
(> = 65) 521 (24.4) 222 (42.6) 299 (57.4)
Patient stratum (n, (%))
ER 447 (20.9) 198 (44.3) 249 (55.7)
Admission 805 (37.7) 297 (36.9) 508 (63.1)
ICU 885 (41.4) 243 (27.5) 642 (72.5)
GOSE (n, (%))
Severe dis. (3, 4) 221 (10.3) 81 (36.7) 140 (63.3)
Moderate dis. (5, 6) 549 (25.7) 185 (33.7) 364 (66.3)
Good recovery (7, 8) 1341 (62.8) 459 (40.9) 882 (65.8)
NA 26 (1.2) 13 (50) 13 (50)
GCS (n, (%))
Severe 340 (16.4) 90 (26.5) 250 (73.5)
Moderate 162 (7.8) 55 (34) 107 (66)
Mild 1571 (75.8) 575 (36.6) 996 (63.4)
Education level (n, (%))
None 23 (1.2) 12 (52.2) 11 (47.8)
Currently studying 58 (3.0) 22 (37.9) 36 (62.1)
Primary school 240 (12.6) 86 (35.8) 154 (64.2)
Secondary/high school 651 (34.1) 213 (32.7) 438 (67.3)
Post high school 402 (21.1) 109 (27.1) 293 (72.9)
University/college 533 (27.9) 209 (39.2) 324 (60.8)
ER = Emergency Room; Admission = patients admitted to hospital wards; ICU = Intensive Care Unit,
GOSE = the Glasgow Outcome Scale, Extended; Severe dis. = patients with severe disability; Moderate dis. = patients
with moderate disability.
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3.2. Descriptive of Variables and Their Reliability
Table 2 shows the descriptive statistics, reliability coefficients, and the intercorrelation of the study
variables. The mean scores for depression (PHQ-9, M = 5.07, SD = 5.35, range = 0–27) and anxiety
symptoms (GAD-7, M = 3.63, SD = 4.54, range = 0–21) were low. Cronbach’s alpha and Guttman’s
lambda 2 of PHQ-9, GAD-7, and PHQ-ADS showed very good internal consistency. The correlation
between PHQ-9 and GAD-7 was high (r = 0.80).
Table 2. The descriptive statistics, reliability coefficients, and the correlation between variables.
α λ2 M SD Min–Max (Q1, Q2, Q3) GAD-7 PHQ-9 PHQ-ADS
GAD-7 0.91 0.91 3.63 4.54 0–21 (0, 2, 6) 1.00
PHQ-9 0.87 0.88 5.07 5.35 0–27 (1, 3, 8) 0.80 1.00
PHQ-ADS 0.94 0.94 8.71 9.40 0–48 (2, 6, 13) 0.94 0.96 1.00
PCL-5 0.93 0.94 12.20 13.61 0–80 (0, 8, 17) 0.76 0.76 0.80
SF-36, PF 0.94 0.94 77.31 26.89 0–100 (65, 90, 100) −0.32 −0.42 −0.39
SF-36, RP 0.95 0.94 64.18 31.94 0–100 (40, 69, 100) −0.44 −0.55 −0.53
SF-36, RE 0.94 0.91 74.56 28.33 0–100 (50, 83, 100) −0.60 −0.65 −0.66
SF-36, SF 0.85 - 75.06 26.49 0–100 (63, 87, 100) −0.56 −0.67 −0.65
SF-36, BP 0.88 - 68.79 27.00 0–100 (51, 74, 100) −0.45 −0.52 −0.51
SF-36, VT 0.84 0.83 57.77 21.86 0–100 (44, 62, 75) −0.58 −0.73 −0.70
SF-36, MH 0.86 0.84 71.49 20.04 0–100 (60, 75, 90) −0.76 −0.76 −0.80
SF-36, GH 0.76 0.73 66.41 22.28 0–100 (50, 70, 82) −0.51 −0.59 −0.58
PHQ-ADS: The Patient Health Questionnaire Anxiety and Depression Scale. M = mean, SD = standard deviation.
Q1 = first quartile, 25%; Q2 = second quartile or median, 50%; Q3 = third quartile, 75%. PF = Physical Functioning;
RP = Role Limitation due to Physical Health; RE = Role Limitation due to Emotional Health; SF = Social Functioning;
BP = Body Pain; VT = Vitality; MH = Mental Health; GH = General Health. Notes: α: Cronbach’s alpha coefficient;
λ2: Lambda 2 of Guttman coefficient; all correlation coefficients were significant at p < 0.001.
3.3. Factorial Structure of PHQ-ADS
As explained in statistical analysis section (also see the descriptive statistics in Table 2 and
Appendix A), we dichotomized responses to 0 (no depression/anxiety) and 1 (some depression/anxiety).
In the parallel analysis (see Appendix B), only one factor seemed to fit the data based on the eigenvalue
of more than one (eigen values: 1st factor = 9.81, 2nd = 0.47, 3rd = 0.32), a sharp break in the scree plot
between the first and the second factor, and the explained variance (explained variance = 0.61).
We compared model fit indices of one-, two-, and bifactorial models estimated within CFA
framework. As can be seen in Table 3, all fit indices had a slight improvement in the bifactorial model.
The chi-square was significant for all models, as is the case with the large sample size; however, the ratio
of χ2-to-df in the two-factorial and bifactorial models was below 3, a threshold that Kline [56] put
for a good fitting model. In the two-factorial model, the correlation between PHQ-9 and GAD-7 was
high (r = 0.91, p < 0.001), implying that one dimension might be able to measure both factors [57].
The bifactorial model seems to be the best fitting model based on the slightly better fit indices.
Table 3. Summary of the Confirmatory Factor Analyses (CFA) for single, two, and bifactorial models of
depression and anxiety.
χ2 (df ) χ2/df p RMSEA a
b RMSEA
95% CI
c SRMR d CFI e TLI f NFI g IFI
One-factorial M. 477.63 (104) 4.49 <0.001 0.042 0.038–0.045 0.048 0.995 0.994 0.994 0.995
Two-factorial M. 308.46 (103) 2.99 <0.001 0.031 0.027–0.035 0.039 0.997 0.997 0.996 0.997
Bifactorial M. 189.76 (88) 2.15 <0.001 0.024 0.019–0.028 0.032 0.999 0.998 0.998 0.999
a RMSEA = root mean squared error of approximation; b RMSEA (95% CI) = 95% confidence interval of root mean
squared error of approximation; c SRMR = standardized root mean square residual; d CFI = comparative fit index;
e TLI = Tucker–Lewis index; f NFI = the Normed Fit Index, g IFI = incremental fit index. Notes: Traditionally,
the standard cut-offs for RMSEA (<0.06) and CFI, TLI, NFI, and IFI (>0.95) indices were used to indicate acceptable
model fit [58]. However, these cut-offs are not validated for WLSMV estimator and therefore we did not interpret
them directly but used them for model comparisons.
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3.4. Factorial Structure Reliability
The Omega coefficients for the general factor (ω = 0.97) and the subscales of depression (ω = 0.92)
and anxiety (ω = 0.94) were excellent. The OmegaH coefficient for a bifactorial model of PHQ-ADS
was 0.87, meaning that 87% of the variance of unit-weighted total scores can be attributed to individual
differences in the general factor (see Appendix C). As a result, most of the reliable variances can be
explained by the general factor and only 10% (ω (0.97)−ωh (0.87)) of the variance in individuals scores
caused by distinct subfactors of PHQ-9 and GAD-7. The ECV coefficient was 0.85, indicating that
the 85% of the common variance was captured by the general factor and the remaining 15% is spread
across subfactors. The general factor explains most of the variance using OmegaH and ECV coefficients
and the subfactors contribution is low in accounting for the individuals’ difference in depression and
anxiety. The PUC coefficient was rather low (PUC = 0.53), implying that perhaps there would be a bias
in considering the test as unidimensional based on the result of ECV.
The percent of common variance due to the general factor was also calculated for each item
(Item Explained Common Variance: I-ECV) and higher scores in I-ECV (≥0.85) indicates the contribution
to the general factor and little contribution to the subfactors which was the case for majority of the items
in this study (Appendix D).
Overall, the omega hierarchical test suggests that GAD-7 and PHQ-9 fit a unidimensional construct
better than the bifactorial model. Further validity tests can examine whether, based on the result of
PUC coefficient, there is a bias in considering the test unidimensional.
3.5. Discriminant Validity
We first categorized the patients based on the cut-off point of 33 in PCL5 into two categories with
0 (no/low PTSD) and 1 (moderate/severe PTSD) values. Logistic regression showed that both PHQ-9
(B = 0.20, z = 8.54, p < 0.001, OR = 1.22 (95% CI: 1.16–1.27)) and GAD-7 (B = 0.20, z = 7.85, p < 0.001,
OR = 1.22 (95% CI: 1.16–1.28)) significantly associated with PCL-5. We also categorized the PHQ-9
and GAD-7 to test which scale would better detect participants with moderate or severe PTSD cases.
With the strict cut-off point of 10 for PHQ-9 and GAD-7, the odd ratios (OR) of correctly classifying
the PTSD cases were 28.73 (95% CI: 19.85–41.59) and 28.11 (95% CI: 19.80–39.90), respectively. With
the lenient cut-off point of 8 for PHQ-9 and GAD-7, the OR of correct classification of PTSD cases were
30.8 (95% CI: 19.92–47.62) and 29.83 (95% CI: 20.80–42.79), respectively.
We categorized the PHQ-ADS into two low and moderate/severe groups based on the cut-off
point of 20 [32] and obtained a higher OR of correct classification of PTSD cases (OR = 41.56, 95%
CI: 28.76–60.06).
3.6. Prevalence, Comorbidity, and Construct Validity
With the use of a stricter cut-off point of 10, the proportion of moderate to severe depression
and anxiety symptoms in our study were 18% and 11%, respectively. With the cut-off point of
8, the prevalence of moderate and moderately severe depression and anxiety were 25% and 16%
respectively. Using the cut-off point of 8, the majority of participants had neither depression nor
anxiety (1526 participants, 72%), and among the rest, 288 (14%) participants had comorbid depression
and anxiety, 245 (12%) had only depression, and 53 (3%) had only anxiety. A total of 54% (288 out of
535) of the moderately/severely depressed patients had comorbid anxiety, and 86% (288 out of 341) of
moderately/severely anxious patients, had comorbid depression.
We examined the association of the PHQ-9 and GAD-7 with the SF-36. The correlation of PHQ-9
and GAD-7 with SF-36 dimensions was significant (Table 2). PHQ-9 had a stronger relationship with
SF-36 dimensions than did GAD-7. Individuals with comorbid depression and anxiety had the lowest
scores on various dimensions of the physical and psychological outcomes and individuals with neither
depression nor anxiety had the highest physical and psychological outcomes score on all dimensions
(Figure 1, for the same analysis with the cut-off point 10 for PHQ-9 and GAD-7 see Appendix E).
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Figure 1. The association of depression and anxiety with physical and mental component scores from
the SF-36v2. Note: PF = Physical Functioning; RP = Role Limitation due to Physical Health; RE = Role
Limitation due to Emotional Health; SF = Social Functioning; BP = Body Pain; VT = Vitality; MH = Mental
Health; GH = General Health; nonD.nonA. = neither depression nor anxiety; A.nonD. = only anxiety;
D.nonA. = only depression; D.A. = comorbid depression and anxiety; with the use of cut-off point of 8
for PHQ-9 and GAD-7; the error bar represents the 95% confidence interval.
3.7. Predictive Validity and Changes of Depression and Anxiety Over Time
Using the cut-off point of 8 for PHQ-9 and GAD-7, there seems to be a significant intra-individual
changes of depression symptoms from three months to six and 12 months, depending on whether
individuals have anxiety in the preceding assessment (Table 4). However, the change of depression
symptoms was not in the direction that was expected as more participants moved from high depression
category to the no/low depression category than the other way around. Individuals’ depression between
six and 12 months did not change as a result of high anxiety. We also conducted a logistic regression to
predict anxiety and depression at six months based on the preceding depression and anxiety symptoms.
In comparison to the participants with no depression and no anxiety, the participants with only
depression symptoms at three months had a higher likelihood of showing anxiety symptoms at six
months (B = 7.67, z = 8.54, p < 0.001, OR = 5.69 (95% CI: 3.64–8.88)) than did the participants with
only anxiety at three months have in showing depression at six months (B = 0.97, z = 2.38, p < 0.001,
OR = 2.64 (95% CI: 1.11–5.61), see Appendix F). Thus, based on the result of McNemar test and logistic
regression, our results did not support the hypothesis that anxiety precedes depression.
In the longitudinal assessment, women had a higher rate of depression and anxiety than men at
all time points (Appendix G). We analyzed the prevalence of the comorbid depression and anxiety over
time (Figure 2) and tested whether individuals changed their group category over time (see Appendix H
for the contingency table). Looking at the distribution of participants at the whole table, 75.9% of
participants from three to six months, 75.3% from three to 12 months, and 79.7% from six to 12 months
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stayed in the same depression and anxiety category. The preceding symptoms had an impact on later
rate of depression and anxiety. Between 88.4% and 90.0% of those with no depression and anxiety
at three-month assessment had no depression and anxiety at six and 12 months post-TBI injury and
between 49.6% and 66.9% of comorbid depression and anxiety still had comorbid depression and
anxiety up to 12 months post-TBI (Appendix H). The McNemar–Bowker Test showed a negligible
change in the probability of off-diagonal change in the contingency table from three to six months
(OR = 1.43, p= 0.558, Cohen’s g= 0.089), from three to 12 months (OR = 1.30, p= 0.565, Cohen’s g= 0.065),
and from six to 12 months (OR = 1.30, p = 0.566, Cohen’s g = 0.066). Thus, there were no significant
differences in probability of change from depression to anxiety, and vice versa (see Appendix H for
contingency Table A4).
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 10 of 20 
 
= 2.38, p < 0.001, OR = 2.64 (95% CI: 1.11–5.61), see Appendix F). Thus, based on the result of McNemar 
test and logistic regression, our results did not support the hypothesis that anxiety precedes depres-
sion.  
In the longitudinal assessment, women had a higher rate of depression and anxiety than men at 
all time points (Appendix G). We analyzed the prevalence of the comorbid depression and anxiety 
over time (Figure 2) and tested whether individuals changed their group category over time (see 
Appendix H for the contingency table). Looking at the distribution of participants at the whole table, 
75.9% of participants from three to six months, 75.3% from three to 12 months, and 79.7% from six to 
12 months stayed in the same depression and anxiety category. The preceding symptoms had an 
impact on later rate of depression and anxiety. Between 88.4% and 90.0% of those with no depression 
and anxiety at three-month assessment had no depression and anxiety at six and 12 months post-TBI 
injury and between 49.6% and 66.9% of comorbid depression and anxiety still had comorbid depres-
sion and anxiety up to 12 months post-TBI (Appendix H). The McNemar–Bowker Test showed a 
negligible change in the probability of off-diagonal change in the contingency table from three to six 
months (OR = 1.43, p = 0.558, Cohen’s g = 0.089), from three to 12 months (OR = 1.30, p = 0.565, Cohen’s 
g = 0.065), and from six to 12 months (OR = 1.30, p = 0.566, Cohen’s g = 0.066). Thus, there were no 
significant differences in probability of change from depression to anxiety, and vice versa (see Ap-
pendix H for contingency Table A4). 
 
Figure 2. The prevalence (%) of depression and anxiety categories at three time points of 3, 6, and 12 
months. Note: F = female; M = male. nonD.nonA. = neither depression nor anxiety; A.nonD. = only 
anxiety; D.nonA. = only depression; D.A. = comorbid depression and anxiety.
Figure 2. The prevalence (%) of depression and anxiety categories at three time points of 3, 6, and 12 months.
Note: F = female; M = male. nonD.nonA. = neither depression nor anxiety; A.nonD. = only anxiety;
D.nonA. = only depression; D.A. = comorbid depression and anxiety.
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Table 4. The McNemar test statistics (chi-squared) for intra-individuals changes of depression over time in low and high anxiety groups using the McNemar
chi-squared test.
Generalized Anxiety Disorder (GAD-7) Categories at 3-Month Based on the Cut-Off Point of 8
Low Anxiety at 3-Months High Anxiety at 3-Months
Matched variable Depression at 6 Mo Depression at 6 Mo
0, n (%) 1, n (%) Total Mc (df), p * 0, n (%) 1, n (%) Total Mc (df), p
Depression at 3 mo 0 1056 (91.6) 97 (8.4) 1153
0.18 (1), p = 0.61 Depression at 3 mo
0 33 (80.5) 8 (19.5) 41 42.61 (1), p < 0.001
1 103 (48.6) 109 (51.4) 212 1 63 (28.0) 162 (72.0) 225
Total 1159 (84.9) 206 (15.1) Total 96 (36.1) 170 (63.9)
Generalized Anxiety Disorder (GAD-7) categories at 3-month based on the cut-off point of 8
Low anxiety at 3-Months High anxiety at 3-Months
Depression at 12 Mo Depression at 12 Mo
0, n (%) 1, n (%) Total Mc (df), p 0, n (%) 1, n (%) Total Mc.(df), p
Depression at 3 mo 0 713 (89.6) 83 (10.4) 796 0.94 (1), p = 0.33 Depression at 3 mo 0 17 (70.8) 7 (29.2) 24 23.17 (1), p < 0.001
1 71 (47.7) 78 (52.3) 149 1 40 (31.5) 87 (68.5) 127
Total 784 (83.0) 161 (17.0) Total 57 (37.7) 94 (62.3)
Generalized Anxiety Disorder (GAD-7) categories at 6-month based on the cut-off point of 8
Low anxiety at 6-Months High anxiety at 6-Months
Depression at 12 Mo Depression at 12 Mo
0, n (%) 1, n (%) Total Mc (df), p 0, n (%) 1, n (%) Total Mc (df), p
Depression at 6 mo 0 818 (90.5) 86 (9.5) 904 8.38 (1), p < 0.01 Depression at 6 mo 0 20 (62.5) 12 (37.5) 32 0.86 (1), p = 0.353
1 52 (39.1) 81 (60.9) 133 1 17 (12.8) 116 (87.2) 133
Total 870 (83.9) 167 (16.1) Total 37 (22.4) 128 (77.6)
* McNemar’s chi-squared (degree of freedom), p-value. Bold: Highlighting the asymmetrical change of depression from earlier to later time point, i.e., individuals that changed their cells
over time.
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4. Discussion
In this study, we examined the factorial structure of a composite measure of depression and
anxiety and evaluated the validity of the subfactors. The results of exploratory and confirmatory
factor analyses, as well as the Omega hierarchical test, suggested a unidimensional construct such
that both instruments were part of a common general factor, as the subscales of PHQ-9 and GAD-7
separately had negligible independent effects to explain the variance of the construct. This is partly
understandable as there are a few similar items in both the subscales, such as being restless and having
trouble relaxing/sleeping. In addition, both depression and anxiety symptoms are part of the same
mood disorder category, share a common domain of negative affect, and share a cognitive process with
negative bias in information processing.
The subfactors of PHQ-9 and GAD-7 performed very similarly in detecting an anxiety-related
disorder, PTSD. Examining the construct validity, both PHQ-9 and GAD-7 subfactors were negatively
related to various domains of physical and psychological outcomes, with PHQ-9 having noticeably
stronger negative relationship with SF-36 subscales than GAD-7 (Table 2, Figure 1). The negative
relationship with SF-36 subscales was much higher for patients with comorbid depression and anxiety.
In addition, the result of our longitudinal analysis did not support the hypothesis that anxiety precedes
depression, as proposed in the literature [52]. Perhaps it is the nature of the traumatic experiences such
as TBI that provides a common cause for the experience of both depression and anxiety symptoms.
on the other hand, it is the social avoidance aspect of the anxiety that is deemed to be a risk factor for
the onset of depression [59,60]. Unfortunately, we did not have a measure for social anxiety in our
study. Besides that, the TBI incidence, the subsequent medical care and potential social support, as well
as the post-TBI recovery process might complicate the relevance of social avoidance aspect of anxiety
for the onset of depression symptoms.
The depression and anxiety symptoms seemed to be stable over time and the small developmental
changes pattern from general anxiety to depression symptoms and vice versa were rather symmetrical
up to one year after TBI. Similarly, in a birth cohort that was followed for 32 years, Moffitt et al. [61]
found that depression also precedes general anxiety symptoms as often as the reverse pattern.
Thus, the developmental changes from one to another requires us to take both pathways into account
and study it with other types of anxiety symptoms as well (for a review, see [59]).
Our findings concern patients after TBI, and this should be borne in mind when seeking
explanations of why depression and anxiety are so closely related. It would be interesting to find out
what shared cognitive processes, or shared biological pathways, contribute to the strong relationship
between depression and anxiety. However, it is not clear if the unidimensionality is because of
the specific traumatic experience in TBI that provides a shared common cause for both depression
and anxiety. Comparative works with depression and anxiety after other types of traumatic events,
e.g., other stressful life events, and comparison with control group can shed more light on this.
Furthermore, it is not clear whether the lack of unique effect of depression and anxiety subfactors is
due to the self-report nature of PHQ-9 and GAD-7 measures. Is the difference between these constructs
more experiential that might be better captured through other research method? Using mixed
methods such as the diagnostic interviews and phenomenological analysis in addition to the self-report
measure can better clarify this point. For instance, with using HADS and structural interviews,
Whelan-Goodinson, Ponsford, and Schönberger [62] found that HADS is a reliable measure of a general
psychological distress construct for patients after TBI and cannot differentiate depressed and anxious
cases identified through structural interviews.
To test the predictive validity, we had only data from three, six, and 12 months after TBI, and it is not
clear if anxiety does not precede depression or if this is not a sufficient time period for anxious patients
to develop depression. As already explained, we included only the general anxiety disorder and
there might be another sub-type of anxiety, such as social anxiety, that might be a risk factor for
the onset of depression. A more comprehensive longitudinal test requires data for a longer period and
information on different sub-types of anxiety symptoms (e.g., social anxiety, phobias), familial and
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contextual factors, as well as the pre-TBI depression and anxiety symptoms. Finally, a more detailed
investigation between PHQ-ADS and more related constructs such as bipolar disorder and suicidality
are required. For instance, one of the items in PHQ-9 has been contested to measure suicidality rather
than depression [38], although the criteria remained in the recent edition of DSM-IV.
Furthermore, we have not investigated the association between depression and other physical,
social, and clinical functioning of the TBI patients given the characteristics of our sample.
Teymoori et al. [45] found that the functional recovery is a much more important predictor of
depression and anxiety severity than the baseline TBI severity, such that individuals with severe
and moderate disability six months after the TBI had higher depression and anxiety symptoms
in comparison to individuals who had a good recovery after the TBI. Noteworthy, TBI severity was
not related to depression and anxiety after controlling for functional recovery measure [45]. Further
analysis regarding the association of depression and anxiety with other physical, social, and clinical
functioning should a task that can be addressed in the future studies.
The debate about whether depression and anxiety scales can actually differentiate the depressed
and anxious people is not new (e.g., see [63]). on the other hand, the result of studies on other scales, such
as HADs, has already shown such inability to differentiate these two constructs through self-reporting
measures. In addition, the high comorbidity and strong correlation between depression and anxiety
might indicate a lack of distinctiveness in measuring what they aim to measure (also see [64]). Our
study shows that PHQ-ADS as a general unidimensional measure is valid and reliable to use for
screening patients for depression and anxiety after TBI and has a good performance in detecting related
construct such as PTSD. Notwithstanding, for an accurate clinical diagnosis and treatment purposes,
detailed medical and psychiatric/psychological evaluations are required.
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Appendix A
Table A1. Descriptive statistics of the items.
n Mean S.D. Min-Max (Q1, Median, Q3) Skewness Kurtosis
GAD7 (Nervous) 2122 0.60 0.80 0–3 (0, 0, 1) 1.36 1.42
GAD7 (NonStopWorry) 2120 0.52 0.83 0–3 (0, 0, 1) 1.61 1.81
GAD7 (WorryTooMuch) 2121 0.62 0.86 0–3 (0, 0, 1) 1.34 1.00
GAD7 (TrblRelax) 2121 0.58 0.85 0–3 (0, 0, 1) 1.45 1.32
GAD7 (Restless) 2120 0.36 0.71 0–3 (0, 0, 1) 2.14 4.17
GAD7 (Annoyed) 2122 0.59 0.84 0–3 (0, 0, 1) 1.41 1.25
GAD7 (Afraid) 2112 0.35 0.73 0–3 (0, 0, 0) 2.26 4.61
PHQ9 (IntrstPleasrActScre) 2125 0.60 0.86 0–3 (0, 0, 1) 1.44 1.32
PHQ9 (DwnDeprssnHopelssScre) 2126 0.55 0.80 0–3 (0, 0, 1) 1.47 1.56
PHQ9 (SleepProbScre) 2125 0.86 1.03 0–3 (0, 1, 1) 0.91 −0.42
PHQ9 (TirdLckEnrgyScre) 2126 1.03 0.99 0–3 (0, 1, 2) 0.69 −0.56
PHQ9 (AppteIssueScre) 2123 0.52 0.87 0–3 (0, 0, 1) 1.64 1.71
PHQ9 (LowSlfEstmScre) 2121 0.42 0.77 0–3 (0, 0, 1) 1.93 3.04
PHQ9 (ConcntrtnProbScre) 2124 0.58 0.88 0–3 (0, 0, 1) 1.46 1.17
PHQ9 (SpdMovmntSpchScre) 2124 0.31 0.71 0–3 (0, 0, 1) 2.47 5.53
PHQ9 (DthHrtThghtScre) 2121 0.18 0.53 0–3 (0, 0, 0) 3.53 13.50
Note: As can be seen in the descriptive statistics, most participants answered that they were not at all or just a few
days of the week bothered by the symptoms of the depression and anxiety. As a result, most participants selected
the lower end of the item responses (0 or 1). For instance, the first quantile, median, and third quantile for the first
item of the PHQ-9 was 0, 0, and 1, and for the first item of GAD-7 was also 0, 0, 1, respectively. As another example,
in response to a question as to on how many days of the last two weeks individuals were afraid something awful
might happen (Item 7 of GAD-7), 1607 participants were not bothered at all (0), 341 for just several days (1), 85 for
more than half the days (2), and 79 participants nearly every day (3).
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Appendix D
Table A2. Standardized Factor Loadings for the General Factor and the Two Sub-Factors of Depression
and Anxiety in Omega Test and CFA.
Schmid–Leiman CFA
Items Gen. Anx. Dep. Communality EV I-ECV Gen. Anx. Dep.
1. PHQ9Int. 0.78 0.33 0.72 0.28 0.85 0.83 *** 0.15 **
2. PHQ9Dwn. 0.85 0.26 0.81 0.19 0.89 0.93 *** −0.02
3. PHQ9Sle. 0.57 0.28 0.41 0.59 0.80 0.59 *** 0.28 ***
4. PHQ9Tir. 0.73 0.38 0.68 0.32 0.78 0.76 *** 0.52 *
5. PHQ9App. 0.64 0.32 0.50 0.50 0.80 0.67 *** 0.19 ***
6. PHQ9Low. 0.77 0.23 0.66 0.34 0.89 0.84 *** −0.06
7. PHQ9Con. 0.69 0.23 0.54 0.46 0.89 0.73 *** 0.10 *
8. PHQ9Spd. 0.67 0.20 0.50 0.50 0.89 0.72 *** −0.02
9. PHQ9Dth. 0.70 0.21 0.55 0.45 0.89 0.76 *** −0.12
10. GAD7Ner. 0.82 0.29 0.76 0.24 0.88 0.84 *** 0.26 ***
11. GAD7Non. 0.83 0.39 0.85 0.15 0.82 0.81 *** 0.45 ***
12. GAD7Wor. 0.79 0.42 0.80 0.20 0.78 0.74 *** 0.57 ***
13. GAD7Trb. 0.82 0.25 0.76 0.24 0.89 0.83 *** 0.26 ***
14. GAD7Res. 0.73 0.25 0.60 0.40 0.88 0.73 *** 0.26 ***
15. GAD7Ann. 0.75 0.22 0.63 0.37 0.90 0.77 *** 0.18 ***
16. GAD7Afr. 0.72 0.31 0.62 0.38 0.84 0.72 *** 0.28 ***
I-ECV: Item Explained Common Variance; EV: Error Variance Note: Schmid–Leiman Factor loadings greater than
0.2; all factor loadings are statistically significant, p < 0.001). For CFA: *** for p < 0.001; ** for p < 0.01; * for p < 0.05.
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greater than 0.2; all factor loadings are statistically significant, p < 0.001). For CFA: *** for p < 0.001; ** 
for p < 0.01; * for p < 0.05. 
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A.nonD 0.97 (0.41) 2.38 *** 2.64 (1.11–5.61) 2.25 (0.37) 6.04 *** 9.53 (4.45–19.46)
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